Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




Oct
17
Today In Oncology
Verifying the Seen and Unseen by AI in Cancer Imaging
AI-Extracted Chart Data for Expanding Surgical Oncology Learnings
Even Highly Curable Childhood Leukemias Take a Substantial Toll on Families
Two Studies Show Breast Cancer Survival and Mortality Gaps Are Widening Between Rural and Urban Areas
Lung Cancer Specialist Apar Kishor Ganti, MD, Shares His Insights
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo